Novo Nordisk’s share worth appreciates after the drug analysis outcomes – the Danish firm is already extra invaluable than your entire Helsinki inventory change
[ad_1]
Danish recognized for its diabetes medicines Novo Nordisk introduced on Tuesday the analysis outcomes of the corporate’s Wegovy drug. Wegovy is called an weight problems drugs.
Within the SELECT trial, the usage of Wegovy diminished the chance of great cardiovascular occasions, reminiscent of coronary heart assault, by 20 % in comparison with the placebo management group.
The goal group of the five-year examine was 17,604 chubby chubby folks aged a minimum of 45 who had been identified with heart problems however no diabetes.
Growth Director of Novo Martin Holst Langen till now, there has not been a weight management drug available on the market that has additionally been discovered to scale back the chance of coronary heart assault, infarction and loss of life associated to cardiovascular illnesses.
Novo plans to current the leads to extra element later this 12 months at a scientific convention. The corporate expects to make functions to the US and European authorities later this 12 months to increase Wegovy’s function of use.
Course in flight
Novo’s share worth on the Copenhagen inventory change rose by 10 % to about 1,200 Danish kroner, or about 161 euros.
In line with Factset, Novo’s share capital totals roughly 2.24 billion shares. Thus, the corporate’s market worth is now round 358 billion euros.
As a degree of comparability, you possibly can take the Helsinki Inventory Alternate, which is probably the most invaluable firm Nordic the market worth is roughly EUR 36 billion. The mixed market worth of the businesses on the primary record of the Helsinki Inventory Alternate is roughly 270 billion euros.
[ad_2]
0 comments